Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
Date: May 4, 2020
Issue #:
1597Summary:
The FDA has approved an orally disintegrating tablet
(ODT) formulation of rimegepant (Nurtec ODT–
Biohaven), a small-molecule calcitonin gene-related
peptide (CGRP) receptor antagonist ( " gepant " ), for
acute treatment of migraine with or without aura
in adults. Rimegepant is the second oral gepant to
become available in the US; ubrogepant(Ubrelvy),
which is approved for the same indication, was the
first. Four parenteral CGRP antagonists, erenumab(Aimovig), fremanezumab(Ajovy), galcanezumab(Emgality), and eptinezumab(Vyepti), are approved
for prevention of migraine.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Aimovig Ajovy Emgality eptinezumab erenumab fremanezumab galcanezumab Imitrex Migraine NSAIDs Nurtec ODT rimegepant Sumatriptan Ubrelvy ubrogepant Vyepti Source Type: research